Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

Platelets are the main effectors of primary hemostasis but also cause thrombosis in pathological conditions. Antiplatelet drugs are the cornerstone for the prevention of adverse cardiovascular events. Monitoring the extent of platelet inhibition is essential. Currently available platelet function te...

Descripción completa

Detalles Bibliográficos
Autores principales: Krammer, Teresa L., Kollars, Marietta, Kyrle, Paul A., Hackl, Matthias, Eichinger, Sabine, Traby, Ludwig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790905/
https://www.ncbi.nlm.nih.gov/pubmed/36578552
http://dx.doi.org/10.3389/fphar.2022.1078722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790905/
https://www.ncbi.nlm.nih.gov/pubmed/36578552
http://dx.doi.org/10.3389/fphar.2022.1078722

Ejemplares similares